Payer & Reimbursement Stakeholders

U.S. private payer with published medical policy and prior-authorization requirements for esketamine (Spravato) in treatment-resistant depression pathways.

U.S. private payer with published psychiatry coverage-position criteria and prior-authorization form requirements specific to Spravato.

Nationwide federal-employee health benefits payer channel (Blue Cross Blue Shield FEP) with published pharmacy policy criteria for Spravato.

Germany’s highest joint self-governing HTA decision body for coverage and evidence appraisal, including esketamine/Spravato dossiers.

IHPI, the Ibogaine Healthcare Policy Institute, is a U.S.-based 501(c)(3) nonprofit focused on policy infrastructure for regulated ibogaine care. Its stated audience includes healthcare decision-makers such as CMS, Medicaid leaders, commercial payers, regulators, and health system executives. The organization says it provides neutral, decision-grade resources on safety, payment, and implementation for ibogaine treatment. IHPI frames its role as building the legal and operational infrastructure needed for regulated ibogaine treatment in the United States, with an emphasis on veterans and people affected by PTSD and opioid use disorder. Its work includes regulatory pathways, safety and delivery standards, and payer system infrastructure such as reimbursement mechanics, coding roadmaps, budget impact logic, and coverage criteria. A published April 2026 explainer indicates it is actively interpreting federal psychedelic policy for downstream implementation, coverage, and delivery questions.

U.S. value assessment organization that publishes comparative effectiveness and cost-effectiveness reports used by payers and policymakers, including assessments relevant to esketamine.

Massachusetts Medicaid payer program with published prior-authorization resources and pharmacy updates that include Spravato-related coverage changes.

Nevada's Medicaid authority publishing pharmacy and physician-administered drug policy materials used for access and prior-authorization decisions, including Spravato-related references in archived DUR and update documents.

State-level Oregon pharmacy and therapeutics decision body supporting evidence-driven formulary and utilization policy.

Australia’s HTA and reimbursement advisory body for PBS listing decisions, including esketamine (Spravato) assessment materials.

U.S. private payer with national provider-facing prior-authorization criteria for Spravato and medical policy criteria that include ketamine/esketamine use conditions.

U.S. Veterans Health Administration payer and formulary authority publishing criteria-for-use and national protocol documents for intranasal esketamine (Spravato).

Canadian pan-jurisdictional payer negotiation body that coordinates joint drug price negotiations for public plans, including completed negotiations for Spravato (esketamine).